Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 362 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Electrocardiogram (ECG) Clear all

Conditions: Age-Related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
Interventions: brolucuzumab 6 mg IVT; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Phoenix, Arizona • Abilene, Texas

Conditions: Schizophrenia
Interventions: SEP363856 150 mg, Placebo, moxifloxacin 400 mg; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 7
States / cities: Little Rock, Arkansas • Long Beach, California • Pico Rivera, California + 4 more

Conditions: High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
Interventions: Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally; Diagnostic Test · Genetic
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Post-Concussion Syndrome
Interventions: Chiropractic adjustment; Procedure
Lead sponsor: Life University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Cardiac Transplant Rejection, Qt Interval, Variation in
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York

Conditions: Postmenopausal Syndrome
Interventions: Estrogen, Progesterone, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions: M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine; Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: American Heart Association; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Fairhope, Alabama • Kankakee, Illinois • Baltimore, Maryland + 3 more

Conditions: Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer, Prostate Cancer
Interventions: EP0057, olaparib, CT scan, CT chest, abdomen, and pelvis, Bone scan, ECG, Echocardiogram, Biopsy; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Surgery
Interventions: ECG; Device
Lead sponsor: Senthil G. Krishna; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acute Myocardial Infarction
Interventions: Not listed
Lead sponsor: Hennepin County Medical Center, Minneapolis; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atrial Fibrillation
Interventions: ECG monitoring with a Kardia Mobile monitor; Other
Lead sponsor: Valley Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: West Des Moines, Iowa • Paramus, New Jersey • Springfield, Oregon

Conditions: Atrial Fibrillation, Cardiovascular Diseases, Arrhythmia, Valvular Disease
Interventions: Risk-Based Assessment for Cardiac Dysfunction; Device
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sleep-disordered Breathing, Snoring
Interventions: CPAP; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis B
Interventions: Bepirovirsen, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Speech
Interventions: MEG/EEG, MRI, Speaking Tasks; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Corticobasal Degeneration, Corticobasal Syndrome, Pain, Neuropathic
Interventions: Scrambler therapy, TENS treatment; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Thalassemia, Iron Overload, Hemochromatosis
Interventions: Nifedipine, Phlebotomy, Urinalysis, Echocardiogram, Electrocardiogram; Drug · Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: ATTR Amyloidosis With Cardiomyopathy, Heart Failure
Interventions: ATTR-CM AI-ECG and AI-Echo Model; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-valvular Atrial Fibrillation
Interventions: Alive Cor Kardia mobile electrocardiogram monitor; Device
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions: COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting; Device · Other
Lead sponsor: Peerbridge Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Pasadena, California • Nashville, Tennessee

Conditions: Drug Toxicity
Interventions: HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Acute exercise, Cold pressor test, Mental stress test; Other
Lead sponsor: University of Massachusetts, Boston; Other
Eligibility: 18 Years to 35 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation, Heart Failure
Interventions: ASSERT Insertable Cardiac Monitor, Conventional Management and monitoring; Device · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

Post-concussion Syndrome and Chiropractic

Home Electrocardiogram (ECG) Monitoring After Heart Transplantation

Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Hypertrophic Cardiomyopathy Federated Learning Implementation Platform

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Effect of Dexmedetomidine on QT Interval in Pediatric Patients Under General Anesthesia

Paced Electrocardiogram Requiring Fast Emergent Coronary Therapy (PERFECT) Study

Cryoballoon vs. Rhythmia Guided Ablation for Recurrent AFib

NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial

Hemodynamics Response to Upper Airway Obstruction in Marfan Syndrome

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Behavioral and Neural Responses to External Alterations of Speech Variability

Scrambler Therapy for Corticobasal Syndrome-Associated Pain

Oral Nifedipine to Treat Iron Overload

Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Neural Control of Kidney Blood Flow During Exercise in African American Adults

Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients